Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time.

Clinical Dementia Rating (CDR) scores can help doctors tell when people with Alzheimer’s disease experience lower ...

We have produced resources about lecanemab for you and your patients. Find out more below. Donanemab (brand name Kisunla®) is a new medication used to treat the very early stages of Alzheimer's ...

Alzheimer's patients with a baseline CDR-SB score of 3.5 could expect approximately 4 additional months (95% CI 2-7 months) ...

Study finds that disease-modifying therapies for Alzheimer’s, lecanemab and donanemab, can extend independence in daily ...

The Centres of Excellence are a groundbreaking initiative developed by Alzheimer’s Society to address areas in dementia care that are in urgent need of more research. You are here: Centres of ...

Imagine you have just been diagnosed with mild cognitive decline due to Alzheimer’s disease. Your doctor might suggest taking ...

More than a decade after hosting clinical trials for two medications now commonly used to slow the progression of Alzheimer’s ...

March 13, 2021 – The New England Journal of Medicine publishes a study indicating that Eli Lilly and Company’s experimental intravenous drug donanemab could slow the cognitive decline of patients with ...

In the past two years, the Food and Drug Administration has approved two novel Alzheimer's therapies, based on data from clinical trials showing that both drugs slowed the progression of the disease.

US researchers behind the new analysis said they hoped the findings would help patients weigh up the potential benefits of ...